Document Detail

Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban Safety study.
MedLine Citation:
PMID:  19952776     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The Sant'ANna TIrofiban Safety study (SANTISS) is an open-label investigator-initiated single-centre registry launched to assess the combination of bleeding and access site in-hospital complications (primary end-point) in patients undergoing percutaneous coronary intervention (PCI) by femoral approach only. METHODS: We compared patients who were on oral single antiaggregating drug (AAD) and received, just prior to PCI, high-dose tirofiban and a second oral antiplatelet agent (triple AAD: group 1, n = 970) with those who were already on an oral double AAD regimen and did not receive tirofiban (double AAD: group 2, n = 608). RESULTS: Group 2 patients were slightly older, presented less frequently with unstable angina and had chronic renal failure more frequently. They were more than twice as frequently on rescue PCI, being more than three-fold less frequently on primary PCI (all: 0.01>P < 0.001). Overall, there were 87 in-hospital (average 4.7 days of stay) complications: 51 (5.3%) in group 1 and 36 (5.9%) in group 2 (not significant). Haemotransfusions were needed in 34 patients: 21 (2.2%) in group 1 and 13 (2.1%) in group 2 (not significant). Of the 16 hospital deaths, eight (0.8%) were seen in group 1 and eight (1.3%) in group 2 (not significant). Multivariate prediction showed a high predictive accuracy (areas under the curve >0.700) of female sex, rescue PCI and chronic renal failure to index complications, with highly significant odds ratios. The presence of high-dose tirofiban did not increase complication risk. CONCLUSION: In the real world, high-dose tirofiban is well tolerated by patients on elective, primary or rescue PCI, and the in-hospital complication rate, including major bleeding, is low. This may have pharmacoeconomic consequences.
Michele Schiariti; Angela Saladini; Bindo Missiroli; Francesco Papalia; Domenico Cuturello; Paolo Emilio Puddu; Carlo Gaudio
Related Documents :
19378676 - Taxus vi final 5-year results: a multicentre, randomised trial comparing polymer-based ...
16275186 - Three-year clinical follow-up after strontium-90/yttrium-90 beta-irradiation for the tr...
16326376 - Bivalirudin compared with iib/iiia inhibitors in patients with in-stent restenosis unde...
19378426 - Inflammatory responses after percutaneous coronary intervention in patients with acute ...
24477666 - Improved visual outcome with early treatment in macular edema secondary to retinal vein...
4095126 - Changes in serum lipoprotein pattern following bezafibrate. differential effects in typ...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of cardiovascular medicine (Hagerstown, Md.)     Volume:  11     ISSN:  1558-2035     ISO Abbreviation:  J Cardiovasc Med (Hagerstown)     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-10     Completed Date:  2010-06-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101259752     Medline TA:  J Cardiovasc Med (Hagerstown)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  250-9     Citation Subset:  IM    
Sant'Anna Hospital, Catanzaro, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary*
Blood Loss, Surgical / statistics & numerical data*
Middle Aged
Platelet Aggregation Inhibitors / administration & dosage*,  adverse effects
Tyrosine / administration & dosage,  adverse effects,  analogs & derivatives*
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 144494-65-5/tirofiban; 55520-40-6/Tyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Epidemiology and patterns of care of patients admitted to Italian intensive cardiac care units: the ...
Next Document:  Screening renal artery angiography in hypertensive patients undergoing coronary angiography and 6-mo...